Arkolith/Insider Trading/INZY/Form 4

Treco Douglas A

CEO, DirectorInozyme Pharma, Inc. (INZY) · full profile →Form 4 · filed Apr 3, 2024
Net Selling
Open-Market Buys
$0
Open-Market Sells
$52K
Net Open-Market Flow
-$52K
Transactions
3
2 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Apr 2, 2024Sell(S)8K$6.94$52K21K
Apr 1, 2024Option exercise(M)25K——28K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Apr 1, 2024Option exercise(M)25K—$075K

Transaction Codes

S
Open-market sale
M
Option exercise / conversion

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0000950170-24-041301) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML